ArticleNature communications2026
ProFormer: generalizable classification of single-cell and plasma proteomes using deep learning.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteins are the main drivers of cell function and disease, making proteomics a powerful technique for biomarker discovery and defining cell identity. While current technologies can profile thousands of proteins and reach single-cell sensitivity, limited throughput restricts applications such as robust classification of large biological or clinical cohorts. To close this gap, we present a deep-learning (DL) approach for the direct analysis of mass spectrometric (MS) data, assigning proteomic profiles to sample identity. Specifically, we introduce the ProFormer, a transformer pipeline that classifies samples by tabular MS1-level features derived from peptide ions, eliminating the need for time-consuming data interpretation. The ProFormer outperforms traditional machine-learning and image-based convolutional neural networks (CNNs), demonstrating enhanced classification and generalization over 14 evaluated architectures. We further provide detailed insights into how the ProFormer dynamically aggregates MS1 data, while preserving signal contribution and enabling explainable AI at single-peptide resolution. Applied to diverse LC-MS data sets, the ProFormer accurately classified single-cell proteomes by cell type, cycle stage or differentiation trajectory, as well as patient disease status from plasma proteomes. Thereby, the ProFormer provides a versatile and rapid framework for the classification of proteomic data, with important implications for patient stratification, early detection and single-cell analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.